The document outlines the discovery and history of insulin, its role in diabetes management, and the types of diabetes (Type I, Type II, and gestational diabetes). It covers insulin administration methods, various insulin formulations, and treatment protocols for hyperglycemia and ketoacidosis. Additionally, the document discusses insulin resistance and the implications of drug interactions on blood sugar levels.

1. INSULIN AND DIABETES MELLITUS
 1921Banting and Best
 1923 Nobel Prize (sharing)
 1926 crystalline form obtained by Abel
 1956-69 chemical and molecular structure
was worked out by Sanger and Hodgkin.
04/23/19 PATKI 1

2. Dog, Margorie was
injected with the
first insulin in
1921
CHARLES H. BEST & FREDERICK G. BANTING
04/23/19 PATKI 2

3.  Alpha cells : Glucagon
 Beta Cells : Insulin
 Delta Cells : Gastrin
 Normal range of Blood glucose: 70 – 120
mg/dl (100 ml)
 Hypoglycemia: < 70 mg/dl
 Diabetes: > 120 mg/dl overnight fasting, 2-
3 hr after meal.
04/23/19 PATKI 3

4. Regulation of Normal blood sugar
Gastrin form
delta cells (islets of
langerhans)
04/23/19 PATKI 4

5. 04/23/19 PATKI 5

6. 04/23/19 PATKI 6

7. 04/23/19 PATKI 7

8. TYPES OF DIABETES
 Type-I : deficiency of insulin (IDDM, Juvenile
onset DM). Type-IA: autoimmune disease of the
pancreatic cell. Type-IB is idiopathic
 Type-II: inadequate insulin (Type II, NIDDM,
Maturity onset DM)
 Gestational Diabetes Mellitus (GDM):
pregnancy and usually resolved during the
postpartum period.
04/23/19 PATKI 8

9. 04/23/19 PATKI 9

10. 04/23/19 PATKI 10

11. Diabetic control
 Blood from vein determines blood glucose
 Value is on day to day basis
 Glycosylated haemoglobin (HbAIC) in RBC is
directly proportional to glucose concentration
over a period of time
 Life span of RBC is 120 days
 6% = 110 mg/dL of blood glucose. Value more
than 8% shows poor control of diabetes.
04/23/19 PATKI 11

12. HbA1c Fasting blood
glucose
OGTT
DIABETES > 6.5% >126mg/dl >200mg/dl
PREDIABETES 5.7-6.4% 100-125mg/dl 140-199mg/dl
NORMAL 5-5.7% <100 mg/dl <140 mg/dl
04/23/19 PATKI 12

13. Common Symptoms Of Hyperglycemia
Classical Symptoms
 Polyphagia (frequently hungry)
 Polyuria (frequently urinating)
 Polydipsia (frequently thirsty)
Other symptoms
 Blurred vision, fatigue, recurrent infections,
weight loss, poor wound healing, dry mouth,
dry or itchy skin, impotence
04/23/19 PATKI 13

14. 04/23/19 PATKI 14

15. 04/23/19 PATKI 15

16. 04/23/19 PATKI 16

17. 04/23/19 PATKI 17

18. GLUT4: Glucose transporter
IRS
IRS
Po4
04/23/19 PATKI 18

19. Glucose Transporters (GLUT)
Glucose entry inhibited
Glucose entry facilitated
• GLUT
GLUT
ABSENCE OF INSULIN PRESENCE OF INSULIN
04/23/19 PATKI 19

20. Determination of diabetic type
C-peptide
 Insulin & C-peptide released in equal amounts
 Type-1 diabetes little or no C-peptide
 Type-2 diabetes typically normal or high.
 C-peptide as biological marker
04/23/19 PATKI 20

21. Insulin administration
 Being a protein, it is degraded in GIT, if
taken orally.
 Generally administered by SC route
 Onset and duration of activity vary among
different preparations
 This is due to the size and composition of
insulin crystals
 The less soluble an insulin is long acting
04/23/19 PATKI 21

22. TYPES OF INSULIN PREPARATIONS
Short Acting Insulin
 Regular Insulin: Soluble clear solution for
I.V. equal to endogenous insulin
 Severe hyperglycemia
 Addition of zinc : Increased solubility,
stability and shelf life
 Addition of protamine : Increased duration
of action
04/23/19 PATKI 22

23. Ultra short acting:
• Lispro, aspart,
• short acting
Plain insulin,
Semi lente
Intermediate acting
NPH(isophane),
Lente
Long acting:
PZI
Ultra lente
glargine, detemer
04/23/19 PATKI 23

24. Long acting insulin
Intermediate long acting
(Lente Insulin, NPH) (Ultralente)
twice daily once daily
NPH: Neutral Protamine Hagedorn
After addition of zinc and protamine
04/23/19 PATKI 24

25. Onset: within 30 minutes
Maximum effect: 1-3 hours
Duration: 8 hours
Short acting
04/23/19 PATKI 25

26. Intermediate acting
Onset: within 1.5 hours
Maximum effect: 4-12 hours
Duration: 24 hours
04/23/19 PATKI 26

27. Long acting
Onset: 1 hour
Duration: 24 hours
04/23/19 PATKI 27

28. Premixed insulins
Onset: within 30 minutes
Maximum effect: 2-8 hours
Duration: 24 hours
04/23/19 PATKI 28

29. Reactions to insulin
 Hypoglycemia: Overdose or failure to eat
or extensive exercise. sympathomimetic
signs are warning. Advise the patients to
carry sugar candy.
 Lipodystrophy: Change the place of
injection or Newer insulins
 Allergy: Use purified insulins
04/23/19 PATKI 29

30. 04/23/19 PATKI 30

31. Newer Insulin
Older insulin: porcine/bovine - contaminants
1. purified by gel filtration
2. After gel filtration further purified by ion
exchange chromatography.
3. Human Insulins: Decombinant DNA
technology (E.coli).
4. Insulin lispro, Insulin aspart, Insulin
Glulisine – short acting
5. Insulin glargine – long acting
04/23/19 PATKI 31

32. Advantages of newer insulins
Less allergic
More stable
Less insulin resistance
Less lipodystrophy
Blood glucose level easily controlled
04/23/19 PATKI 32

33. Normal insulin
Lispro insulin
04/23/19 PATKI 33

34. LISPRO INSULIN
Lispro insulin + Phenolic Regular
compound insulin
Phenolic compound
Monomere Dimere
Rapid onset Monomere
Post prandial
control
Slow onset
04/23/19 PATKI 34

35. 04/23/19 PATKI 35

36. LISPRO INSULIN
28th and 29th amino acids on the insulin B
chain, lysine and proline = Lispro
Type of insulin Onset Peak
effect
Duration
Lispro Insulin
(rapid acting)
0-15
min
30 – 90
min
< 5 hr
Regular Insulin
(short acting)
30 – 45
min
2 – 4 hr 6 – 8 hr
04/23/19 PATKI 36

37. Insulin aspart
 Apartic acid at B28
Insulin Glulisine
 Lysine at B23 and Glutamic acid at B29
 Advantages and actions are similar to
Insulin lispro
04/23/19 PATKI 37

38. 04/23/19 PATKI 38

39. 04/23/19 PATKI 39

40. INSULIN GLARGINE
 Onset of action: 1-1½ hours
 Maximum effect: 4-6 hours (peakless)
 Duration of action: 24 Hours (ultra long
acting)
 Don’t mix with other insulin preparations in
the same syringe – it is acidic (pH 4)
 Absorption pattern: independent of
anatomic site of injection
 Less immunogenicity
 6-7 fold greater binding than native insulin04/23/19 PATKI 40

41. Insulin syringes:
Prefilled insulin
syringes
Pen devices: Syringes resemble
pen, preset amount propelled
through a trigger
NEWER INSULIN DELIVERY DEVICES
04/23/19 PATKI 41

42. NEWER INSULIN DELIVERY DEVICES
Jet injectors: Insulin pumps:
Painless rapid Insulin is infused
delivery through at a calculated rate
needless device
Nasal insulin delivery
Rectal and subcutaneous pellets:
04/23/19 PATKI 42

43. DRUG INTERACTIONS
 Beta adrenergic blockers suppress warning
signs
 Thiazides, frusemide, corticosteroids, oral
contraceptives, salbutamol, calcium channel
blockers raise the blood sugar by inhibiting the
insulin secretion.
 Alcohol precipitates hypoglycemia (depleting
breaking the glycogen)
 Salicylates, lithium and theophylline enhance
insulin secretion and peripheral glucose
utilization resulting the hypoglycemia.
04/23/19 PATKI 43

44. USES OF INSULIN
Infection and ketoacidosis: Short term
use
Long term use is advised in CVS, retinal,
renal, neurological conditions etc.
IDDM: compulsory use
NIDDM: it is advised
a. Failure of oral hypoglycaemic agents.
b. Temporary use in infection, trauma,
surgery, pregnancy.
04/23/19 PATKI 44

45. INSULIN RESISTANCE
Requirement of insulin: more than 200
U/day
May be due to antibodies production
Resistance should be in the absence of
ketoacidosis, Infection or stress.
Select more purified newer insulin
Oral hypoglycemic agents may be added
04/23/19 PATKI 45

46. Symptoms of Ketoacidosis
high blood sugar levels
frequent urination (polyuria) and thirst
fatigue and lethargy
nausea
vomiting
abdominal pain
fruity odor to breath
rapid, deep breathing
muscle stiffness or aching
coma
04/23/19 PATKI 46

47. Treatment of Ketoacidosis
Regular insulin by i.v.
i.v. fluids
KCl
Bicarbonate to correct acidosis
Phosphate (when required)
Antibiotics
04/23/19 PATKI 47

48. GLUCAGON
 Alpha cells of islets of Langerhans
 Hyperglycemic hormone
 It is inactive orally
 It is used in severe hypoglycemia
where glucose administration is
impossible.
 It is also used as a diagnostic agent.
04/23/19 PATKI 48

49. THANKS FOR WATCHING
COMMENTS PL
drpatki@gmail.com
04/23/19 PATKI 49